کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8725745 | 1589963 | 2017 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Papel de la ribavirina en la terapia libre de interferón frente al virus de la hepatitis C
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Papel de la ribavirina en la terapia libre de interferón frente al virus de la hepatitis C Papel de la ribavirina en la terapia libre de interferón frente al virus de la hepatitis C](/preview/png/8725745.png)
چکیده انگلیسی
Interferon-free regimens achieve sustained virologic response (SVR) rates of over 90%, have generally well-tolerated adverse effects and involve 12-week treatment durations for most patients with chronic hepatitis C, including naive or previously treated patients and patients with or without cirrhosis. However, some of the treatment options recommended by the guidelines require the addition of ribavirin (RBV) or extend the duration of treatment to increase efficacy. The use of RBV is a useful tool in those difficult-to-cure patients such as patients with decompensated or genotype-3-infected cirrhosis and those who have not achieved SVR after treatment with direct-acting antivirals (DAA). Overall, adding RBV to the different combinations causes adverse effects related to a decrease in haemoglobin and involves inconveniences such as its dosage, which requires patients to take several tablets twice daily. However, severe anaemia is rare and easily manageable with a dose reduction. In addition, RBV is teratogenic. In practice, because RBV is inexpensive and well tolerated when combined with an interferon-free regimen, it continues to be a useful tool to optimise the results of some HCV treatment regimens. RBV-free regimens eliminate RBV-related adverse effects related, resulting in better tolerability, improving patient adherence and quality of life and reducing the cost of treatment.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: GastroenterologÃa y HepatologÃa - Volume 40, Issue 10, December 2017, Pages 699-708
Journal: GastroenterologÃa y HepatologÃa - Volume 40, Issue 10, December 2017, Pages 699-708
نویسندگان
Rosa Maria Morillas, Helena Masnou, Mercé Ardévol, Dulce López,